OC
OCS.US Oculis Holding AG Ordinary shares
- Market cap
- USD 425M
- P/E
- -
- P/B
- 1.70x
- ROE
- -36.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OCS.US undervalued?
Graham numberThe Graham number of Oculis Holding AG Ordinary shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oculis Holding AG Ordinary shares fundamental analysis
No fundamental analysis for Oculis Holding AG Ordinary shares yet.
Oculis Holding AG Ordinary shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; an…
Full company profileOculis Holding AG Ordinary shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oculis Holding AG Ordinary shares annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 993K | 960K | 912K | 883K | 686K | 0.00 | 9.33K |
| Gross Profit | -8.34M | -8.61M | -21.3M | -28.4M | -51.4M | - | - |
| Operating Income | -12.3M | -13.2M | -32.4M | -80.7M | -73.2M | -79.1M | -92.8M |
| EBITDA | -12.1M | -13.2M | -31.9M | -87.1M | -85.5M | -93.3M | -75.2M |
| Net Income | -14.9M | -18.6M | -38.7M | -88.8M | -85.8M | -94.5M | -76.9M |
| EPS | -0.45 | -0.57 | -1.18 | -2.97 | -2.12 | -1.81 | -1.24 |
| Balance Sheet | |||||||
| Total Assets | 16.4M | 58.0M | 37.1M | 114M | 120M | 236M | 232M |
| Total Liabilities | 60.0M | 119M | 135M | 20.6M | 47.0M | 39.9M | 23.6M |
| Shareholders' Equity | -43.7M | -61.0M | -98.0M | 93.7M | 73.4M | 196M | 209M |
| Cash & Short-term Investments | 4.95M | 46.3M | 19.8M | 91.7M | 98.7M | 213M | 210M |
| Total Debt | 54.8M | 114M | 123M | 605K | 1.18M | 2.32M | 2.79M |
| Cash Flow | |||||||
| Operating Cash Flow | -12.0M | -13.8M | -25.1M | -53.8M | -47.5M | -62.2M | -73.0M |
| Capital Expenditure | 19.0K | 28.0K | 3.55M | 48.0K | 230K | 287K | 28.7K |
| Free Cash Flow | -12.0M | -13.9M | -28.6M | -53.9M | -47.7M | -62.5M | -72.0M |
| Ratios | |||||||
| ROE | - | - | - | -94.7% | -116.9% | -48.1% | -36.9% |
| ROA | -90.8% | -32.0% | -104.4% | -77.7% | -71.3% | -40.0% | -33.1% |
| Net Profit Margin | -1,497.8% | -1,932.5% | -4,243.2% | -10,056.9% | -12,503.9% | - | -824,308.3% |
| Debt to Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oculis Holding AG Ordinary shares dividends
Oculis Holding AG Ordinary shares has not paid dividends in the last 6 fiscal years.
Who owns Oculis Holding AG Ordinary shares
- Insiders 3.82%
- Institutions 48.00%
- Public & others 48.18%
- Shares outstanding 55.7M
- Free float 51.6M
Top funds holding OCS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 994K | 1.78% | 0.00% | Sep 2026 |
| abrdn Healthcare Opportunities | 717K | 1.29% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 604K | 1.08% | -29.38% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 582K | 1.05% | 0.00% | Sep 2026 |
| abrdn World Healthcare | 488K | 0.88% | 0.00% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 421K | 0.75% | 0.00% | Apr 2026 |
| Franklin Biotechnology Discovery A | 315K | 0.56% | 0.00% | Sep 2026 |
| Stefnir Icelandic Growth | 314K | 0.56% | -3.91% | Sep 2026 |
| abrdn Life Sciences Investors | 295K | 0.53% | -16.32% | Oct 2026 |
| Eaton Vance Glbl Macro Abs Ret Advtg I | 110K | 0.20% | 0.00% | Jul 2026 |
| ALPS Medical Breakthroughs ETF | 75.4K | 0.14% | 0.00% | Oct 2026 |
| Vanguard International Explorer Inv | 70.7K | 0.13% | -33.04% | Sep 2026 |
| Hartford Small Company Y | 69.2K | 0.12% | 0.00% | Sep 2026 |
| PPF Helix Biotechnology I USD | 48.2K | 0.09% | +18.67% | Jul 2026 |
| Hartford Small Company HLS IA | 45.4K | 0.08% | 0.00% | Sep 2026 |
| Stefnir Balanced Fund | 30.0K | 0.05% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 28.6K | 0.05% | 0.00% | Oct 2026 |
| JHVIT Small Cap Stock NAV | 28.2K | 0.05% | 0.00% | Sep 2026 |
| Manulife GF Healthcare AA | 27.1K | 0.05% | 0.00% | Sep 2026 |
| Eaton Vance Glbl Macr Absolute Return I | 26.9K | 0.05% | 0.00% | Jul 2026 |
Top institutions holding OCS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| EQT Fund Management S.à r.l. | 6.95M | 12.47% | 0.00% | Sep 2026 |
| Aberdeen Group PLC | 2.28M | 4.09% | +5.49% | Sep 2026 |
| Millennium Management LLC | 2.04M | 3.67% | +123.70% | Jun 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.66M | 2.98% | +10.13% | Sep 2026 |
| Citadel Advisors Llc | 987K | 1.77% | +512.09% | Jun 2026 |
| BRAIDWELL LP | 834K | 1.50% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 809K | 1.45% | +63.79% | Jun 2026 |
| Saturn V Capital Management LLC | 685K | 1.23% | +32.53% | Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 641K | 1.15% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 625K | 1.12% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 620K | 1.11% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 540K | 0.97% | -59.87% | Jun 2026 |
| Partner Fund Management LP | 436K | 0.78% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 435K | 0.78% | 0.00% | Jun 2026 |
| Manufacturers Life Insurance Co | 399K | 0.72% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 395K | 0.71% | 0.00% | Jun 2026 |
| SYQUANT CAPITAL SAS | 375K | 0.67% | +68.26% | Jun 2026 |
| Nan Fung Group Holdings Ltd | 301K | 0.54% | -14.31% | Jun 2026 |
| Qube Research & Technologies | 262K | 0.47% | +1,179.22% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 225K | 0.40% | +239.81% | Jun 2026 |
Oculis Holding AG Ordinary shares company profile
- Company name
- Oculis Holding AG Ordinary shares
- Ticker
- OCS.US
- ISIN
- CH1242303498
- Exchange
- USA Stocks
- Listed since
- Mar 2, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Fiscal year end
- December
- Address
- Bahnhofstrasse 20, Zug, Switzerland, 6300
- Phone
- 41 41 711 3960
- Website
- oculis.com
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Oculis Holding AG Ordinary shares management
10- Dr. Riad Sherif M.B.A., M.D.CEO & Director · born 1968
- Ms. Sylvia CheungChief Financial Officer · born 1975
- Ms. Gudrun Bachmann Ph.D.Chief Technology Officer
- Prof. Bjorn Tackenberg M.D., Ph.D.Chief Scientific Officer
- Ms. Katie A. KazemChief Legal & Compliance Officer
- Ms. Virginia R. DeanChief Human Resources Officer · born 1966
- Mr. Páll Ragnar JóhannessonChief Business Officer · born 1982
- Ms. Rebecca Weil Ph.D.Chief Commercial Officer
- Dr. Snehal Shah Pharm.D.President of Research & Development
- Dr. Sharon Klier M.D., M.P.H.Chief Development Officer